首页> Statistics in medicine> BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint

BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint

导出原文传递

翻译打印收藏纠错

第一作者： Beibei Guo

作者： Beibei Guo ^[1] ; Yong Zang ^[2]

作者单位： Department of Experimental Statistics,Louisiana State University ^[1] Department of Biostatistics and Health Data Science,Indiana University ^[2]

关键词 Bayesian adaptive design biomarker dose finding immune response immunotherapy phase I/II trial progression‐free survival risk‐benefit tradeoff subgroups

发布时间 2023-01-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Statistics in medicine

2022年41卷7期

1205-1224页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Statistics in medicine

2022年41卷7期

1205-1224页

检索历史清除

BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint

Statistics in medicine

相似文献

同项目论文

Statistics in medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint

Statistics in medicine

相似文献

同项目论文

Statistics in medicine

相关期刊

检索历史清除